Clin2
NCT06903117Possibly a fitRecruiting

CAR T-Cell Therapy for CEA-Positive Advanced Lung Cancer

Advanced Lung Cancer

Treatments studied

Part of Cancer, Lungs & breathing clinical trials.

This early-stage trial tests a special immune cell treatment (CAR T cells) designed to target and attack lung cancer cells that have a protein called CEA on their surface. It's for people with advanced lung cancer who have already tried at least two standard treatments without success.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 1
Enrollment
60 people
Ages
18 years and older
Study type
Interventional

Who can take part

  • You are 18 years or older.
  • You have advanced, metastatic, or recurrent lung cancer (non-small cell or small cell) that has not responded to or you couldn't tolerate at least two prior standard treatments.
  • Your recent tumor tissue or blood test shows your cancer cells make a marker called CEA (carcinoembryonic antigen).
  • You have at least one tumor that can be measured on scans (at least 1 cm in size for most, or 1.5 cm for lymph nodes).
  • You are in reasonably good health overall, with normal blood counts, heart, kidney, and liver function.
  • You agree to use reliable birth control for one year after the cell infusion.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06992583Recruiting· Phase 1
CAR-T cell therapy for advanced CEA-positive lung cancer

This trial tests a new type of immune therapy called CAR-T cells that are designed to attack lung cancer cells with a specific marker called CEA. It may be an option for people with advanced lung cancer who have already tried other treatments.

Nanjing, Jiangsu
NCT06945523Recruiting· Phase 1
CAR-T cell therapy for CEA-positive advanced lung cancer

This trial tests a treatment using your own immune cells, modified to target a protein called CEA on lung cancer cells. It's for people with advanced lung cancer that has gotten worse after at least one prior treatment.

Wuhan, Hubei
NCT06768151Recruiting· Phase 1
CEA-targeting car-t therapy for advanced lung cancer

This trial tests a new treatment called CAR-T therapy that targets a protein called CEA found on some lung cancer cells. It is for people with advanced lung cancer that has not responded to or has gotten worse after at least two standard treatments.

Wuhan, Hubei
NCT07250386Recruiting· Phase 1
CEA-targeted CAR-T therapy for advanced solid tumors

This trial tests a new CAR-T cell therapy that targets CEA, a protein found on certain cancer cells. It's for people with advanced solid tumors like lung or breast cancer who have not responded to other treatments.

Hangzhou, Zhejiang
NCT06043466Recruiting· Phase 1
CAR-T cell therapy for CEA-positive advanced solid tumors

This trial tests a new cell therapy called CAR-T that targets cancer cells with a protein called CEA. It is for people with certain advanced cancers that have not responded to standard treatments.

Hangzhou, Zhejiang
NCT06821048Recruiting· Phase 1
CAR-T cells targeting CEA for advanced solid tumors

This trial tests a new treatment called CAR-T cells that are designed to attack cancer cells positive for CEA protein. It's for people with advanced solid tumors like colorectal or lung cancer who have run out of standard options.

Hangzhou, Zhejiang

Hear when a new Advanced Lung Cancer trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.